NCT02041195View on ClinicalTrials.gov

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

December 31, 2014

Conditions
Overweight and Obesity
Interventions
DRUG

Setmelanotide

DRUG

Placebo

Trial Locations (2)

Unknown

Dallas

Madison

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY

NCT02041195 - Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients | Biotech Hunter | Biotech Hunter